H
0.587
0.00 (-0.51%)
| Previous Close | 0.590 |
| Open | 0.600 |
| Volume | 1,697,784 |
| Avg. Volume (3M) | 2,910,937 |
| Market Cap | 426,240,064 |
| Price / Earnings (Forward) | 26.04 |
| Price / Sales | 0.320 |
| Price / Book | 0.770 |
| 52 Weeks Range |
| Profit Margin | -1.27% |
| Operating Margin (TTM) | -1.43% |
| Diluted EPS (TTM) | -0.960 |
| Quarterly Revenue Growth (YOY) | 6.70% |
| Total Debt/Equity (MRQ) | 136.23% |
| Current Ratio (MRQ) | 1.29 |
| Operating Cash Flow (TTM) | 338.50 M |
| Levered Free Cash Flow (TTM) | -195.19 M |
| Return on Assets (TTM) | 1.34% |
| Return on Equity (TTM) | -3.08% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (AU) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | HEALIUS FPO [HLS] | - | - |
AIStockmoo Score
0.1
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.13 |
|
Healius is Australia’s second-largest pathology provider. Pathology revenue is almost entirely earned via the public health Medicare system and makes up the majority of Healius' group revenue. A small portion comes from its clinical testing business, Agilex. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 2.18% |
| % Held by Institutions | 70.51% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |